CSRxP Statement On The Trump Administration’s Proposal To Change Medicare Drug Prices

10-25-2018 Press Release

For Immediate Release: Contact: Lauren Blair (201) 213-5004 [email protected] The Campaign for Sustainable Rx Pricing (CSRxP) issued the following statement in response to the U.S. Department of Health and Human Services’ (HHS) new proposal regarding Medicare drug prices: “We’re pleased to see that the Trump Administration continues to focus on lowering out-of-control drug prices for […]

CSRxP Statement On PhRMA’s DTC Advertising Announcement

10-15-2018 Press Release

The Campaign for Sustainable Rx Pricing (CSRxP) issued the following statement in response to PhRMA’s announcement today on changes member companies are making to their direct-to-consumer television advertisements:   “PhRMA’s ‘big announcement’ today is a joke since drug pricing can already be found online.  The solution is simple and has bipartisan support: providing real and direct drug […]

CSRxP Statement On HHS DTC Advertising Announcement

10-15-2018 Press Release

CSRxP issued the following statement in response to the U.S. Department of Health and Human Services’ (HHS) announcement on direct-to-consumer (DTC) television advertisements:   “Today, the Trump Administration made real progress toward ensuring consumers have the information they need to make the health care decisions that are best for them.  Consumers have the right to know how much medicines […]

Congress Rejects Big Pharma Bailout

09-26-2018 Press Release

Defeat For Price-Gouging Drug Manufacturers; Victory For Taxpayers & Patients   For Immediate Release: Contact: Lauren Blair (201) 213-5004 [email protected] The Campaign for Sustainable Rx Pricing released the following statement after House and Senate Committee leaders introduced the Opioid Crisis Response Act of 2018 without changes to the Medicare Part D program, which would have […]

CSRxP Urges Congress to Stop Big Pharma’s $4 Billion Bailout

09-25-2018 Press Release

Washington, D.C. – Today the Campaign for Sustainable Rx Pricing, joined by several groups committed to lowering drug prices, sent a letter to Senate Majority Leader Mitch McConnell, Senate Minority Leader Chuck Schumer, House Speaker Paul Ryan and House Minority Leader Nancy Pelosi, urging them not to include a multi-billion dollar bailout for Big Pharma […]

CSRxP Statement on Potential Big Pharma Bailout

09-21-2018 Press ReleaseUncategorized

“Only Big Pharma would use bipartisan opioid legislation as another opportunity to make money off the very crisis they themselves created. The focus of this effort is no longer about helping communities affected by the opioid epidemic, it’s about further enriching Big Pharma on the backs of seniors, while hoping no one notices. For all the […]

CSRxP Urges House Members To Maintain Transparency Provision In Senate-Passed Appropriations Bill

08-29-2018 Press Release

CSRxP-Supported Policy Enables HHS To Require Drug Price Disclosure In Direct-To-Consumer Advertising Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) sent a letter urging members of the U.S. House Committee on Appropriations to maintain a provision in the Senate-passed appropriations “minibus” package that would provide funding to enable the U.S. Department of Health […]

CSRxP Applauds Senate Action To Boost Drug Price Transparency For Consumers

08-24-2018 Press Release

Legislation Includes CSRxP-Supported Amendment Enabling HHS To Require Disclosure of Drug Prices in Direct-to-Consumer Advertising   The Campaign for Sustainable Rx Pricing issued the following statement after the Senate took action to enhance drug pricing transparency by passing legislation that included a CSRxP-supported amendment – introduced by Senator Dick Durbin (D-IL) and Senator Chuck Grassley (R-IA) – […]

Statement on Celgene’s Revlimid Price Hike

07-10-2018 Press Release

CSRxP spokesman Will Holley released the following statement in response to today’s report that Celgene will once again raise the price of Revlimid: “Today’s announcement that Celgene is yet again raising the price of Revlimid demonstrates very clearly the failures of the prescription drug market in the United States.  Over the last 18 months, Celgene […]

CSRxP Applauds Secretary Azar’s Focus on List Prices

06-26-2018 Press Release

CSRxP spokesman Will Holley released the following statement in response to Secretary Azar’s testimony in front of the Senate Finance Committee today: “The Administration’s focus on out-of-control list and launch prices is a step in the right direction towards our shared goal of more-affordable prescription drugs.  In particular, we were encouraged to hear Secretary Azar’s response […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.